Image courtesy by QUE.com
For two decades, the odds of a second stroke have barely moved. On Monday, the U.S. Food and Drug Administration approved a drug that Bayer hopes will finally change that. Sunharbo (asundexian) is the first medicine cleared in the United States that blocks a clotting protein called Factor XIa, opening a new class of blood thinners and giving Bayer a potential blockbuster just as its older anticoagulant franchise fades.
The approval matters well beyond neurology clinics. It is a test of whether a new mechanism can deliver protection against clots without the bleeding risk that has limited blood thinners for years, and it sets up a high-stakes race with Bristol Myers Squibb, Johnson & Johnson and Novartis for a market analysts value in the tens of billions.
What the FDA Approved
According to the FDA's announcement, Sunharbo 50 mg tablets are approved, taken once daily alongside standard antiplatelet therapy, to reduce stroke risk in adults after a recent mild-to-moderate ischemic stroke that was not caused by a clot from the heart, or after a high-risk transient ischemic attack, the episode often called a "mini-stroke." The agency had granted the drug Fast Track and Priority Review designations.
The label has clear boundaries. Sunharbo is not approved for stroke prevention in patients with atrial fibrillation, is not recommended for people with moderate or severe liver impairment, and should be paused at least 24 hours before elective surgery and for at least 24 hours after clot-busting treatment for an acute stroke, the FDA said.
Stroke remains one of the leading causes of death in the U.S., and Bayer estimates about 795,000 Americans experience one each year, Reuters reported.
The Trial Numbers Behind the Decision
The approval rests on OCEANIC-STROKE, a Phase 3 study that randomized 12,327 patients with a mean age of 68 to either Sunharbo or placebo, both on top of antiplatelet drugs, within 72 hours of symptoms. Bayer's announcement lays out the headline results:
- Ischemic stroke fell 26% versus placebo, occurring in 6.2% of Sunharbo patients compared with 8.4% on placebo.
- Major bleeding was similar between the groups, at 1.6 versus 1.5 events per 100 person-years.
- The combined rate of cardiovascular death, heart attack or stroke dropped to 9.2% from 11.1%.
- Gastrointestinal bleeding was higher on the drug, at 2.7 versus 2.1 per 100 patient-years, and the drug was associated with raised liver enzymes, most of them mild.
The FDA added an important nuance: while overall major bleeding was similar, it was increased with Sunharbo in patients older than 75 and during the first 90 days of treatment. Cardiology outlet TCTMD noted the 26% relative reduction translates to an absolute reduction of 2.2 percentage points over up to two years of follow-up, and that later analyses suggested the drug also lessens the severity of strokes that still occur.
Why a New Clotting Target Is a Big Deal
Today's best-selling anticoagulants, Eliquis from Pfizer and Bristol Myers Squibb and Xarelto from Johnson & Johnson and Bayer, work by blocking Factor Xa. Factor XIa sits at a different point in the clotting cascade, and the long-running scientific bet is that targeting it can stop dangerous clots while leaving more of the body's ability to stop bleeding intact.
That bet has not paid off everywhere. Bayer's own atrial fibrillation trial of asundexian failed, which is why the approval is confined to secondary stroke prevention. Still, a stroke drug that cut recurrences without a clear jump in major bleeding is a meaningful proof of concept for the whole class. "There have not been any changes in the recurrence rates of stroke over the past 20 years," Sebastian Guth, president of Bayer's U.S. operations, told Reuters.
The Business Stakes for Bayer
For Bayer, the timing is critical. Xarelto revenue has been shrinking as cheaper generics arrive, and the company has described asundexian as having blockbuster potential, which typically means more than $1 billion in annual sales. According to pharmaphorum, analysts have floated peak sales of around €3 billion, while Bayer's publicly shared internal forecast is closer to €1 billion after the atrial fibrillation setback.
Bank of America analysts, as reported by ARIVA.DE, put the market consensus near €2 billion and size the secondary stroke prevention market in the low double-digit billions of euros, with atrial fibrillation worth roughly €20 billion. China's regulator approved the drug late last month, and Bayer expects U.S. shipments to begin in mid-to-late November.
Price, Access and the Competition
Bayer set a list price of $748.50 for a 30-day supply. The company says most patients and health plans will not pay the list price and points to its patient assistance foundation, but cost is already flagged as the main hurdle. Wake Forest neurologist Cheryl Bushnell told TCTMD that cost is "probably going to be the main limiting factor." For employers and insurers, a new chronic therapy at roughly $9,000 a year at list price for a large stroke-survivor population will be a formulary decision to watch.
Bayer's head start may not last long. Milvexian, the Factor XIa drug from Bristol Myers Squibb and Johnson & Johnson, is expected to report stroke-prevention data this quarter and atrial fibrillation results in early 2027, while Novartis is developing abelacimab. Bank of America sees a milvexian win in both indications as the biggest risk to Bayer, since a broad label in atrial fibrillation could bring wider adoption and pricing pressure.
What It Means for Business Readers
Three takeaways stand out. First, first-in-class approvals still move the needle for big pharma facing patent cliffs, and Bayer now has a growth product in a category it knows well. Second, the real commercial prize remains atrial fibrillation, so the next readouts from rivals will shape the class's value more than this approval alone. Third, payers, hospital systems and benefits managers should expect a fresh round of pricing and coverage debates as Factor XIa drugs move from trials into everyday prescribing.
The Bottom Line
Sunharbo gives stroke survivors a new option for the first time in years and gives Bayer a credible successor to Xarelto. Whether it becomes a true blockbuster will depend on price, on how doctors weigh the extra gastrointestinal bleeding in older patients, and on how fast competitors arrive with data of their own.
Never miss a patient call. Clinics, pharmacies and health practices lose bookings when calls go to voicemail. MAJ.COM Voice AI puts 24/7 AI voice agents on every inbound call and handles outbound sales and customer support, so your business never misses a lead.
Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous
Articles published by QUE.COM Intelligence via Yehey.com website.
0 Comments